December 10, 2015
Video
Patricia L. Kropf, MD, discusses a combination of decitabine and arsenic trioxide as a replacement for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who cannot withstand induction chemotherapy.